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Putative function and physiological relevance of the
mitochondrial uncoupling protein-3: Involvement
in fatty acid metabolism?
Patrick Schrauwen a,*, Joris Hoeks a, Matthijs K.C. Hesselink b
a Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Department of Human Biology, Maastricht University,
P.O. Box 616, 6200 MD, Maastricht, The Netherlands
b Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Department of Movement Sciences, Maastricht University,
P.O. Box 616, 6200 MD, Maastricht, The NetherlandsAbstract
The discovery of the human homologue of the thermogenic protein UCP1, named uncoupling protein 3 (UCP3),
boosted research on the role of this skeletal muscle protein in energy metabolism and body weight regulation. Nowadays,
9 years after its discovery emerging data indicate that the primary physiological role of UCP3 may be the mitochondrial
handling of fatty acids rather than regulating energy expenditure via thermogenesis. UCP3 has been proposed to export
fatty acid anions or fatty acid peroxides away from the matrix-side of the mitochondrial inner membrane to prevent their
deleterious accumulation. In this way, UCP3 could protect mitochondria against lipid-induced oxidative mitochondrial
damage, a function especially important under conditions of high fatty acid supply to skeletal muscle mitochondria. Such
function may be clinically relevant in the development of type 2 diabetes mellitus, a condition characterized by muscular
fat accumulation, mitochondrial damage and low levels of UCP3.
 2005 Elsevier Ltd. All rights reserved.





th1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18








E-m2.1. Mechanism of action for mitochondrial uncoupling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20827/$ - see front matter  2005 Elsevier Ltd. All rights reserved.
1016/j.plipres.2005.11.001
breviations: ACS, acyl-CoA synthase; BAT, brown adipose tissue; CPT, carnitine palmitoyltransferase; CRE, cyclic AMP response
t; DNP, 2,4-dinitrophenol; FCCP, carbonylcyanide p-trifluoromethoxyphenylhydrazone (an uncoupling reagent); KO, knock-out
ls); MEF, myocyte enhancher factor; MtDNA, mitochondrial DNA; MTE, mitochondrial (acyl-CoA) thioesterase; PPAR, per-
e proliferator activated receptor; RMR, resting metabolic rate; ROS, reactive oxygen species; RXR, retinoid X receptor; TRE,
-responsive element; T3, triiodothyronine; UCP, uncoupling protein; WAT, white adipose tissue.
rresponding author. Tel.: +31 43 3881502; fax: +31 43 3670976.
ail address: p.schrauwen@hb.unimaas.nl (P. Schrauwen).
18 P. Schrauwen et al. / Progress in Lipid Research 45 (2006) 17–412.2. Reconstitution of UCP3 in cell systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.3. Genetic manipulation of UCP3 in animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213. Regulation of UCP3 gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
3.1. UCP3 gene structure and protein distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
3.2. Potential transcriptional regulatory sites of the UCP3 gene. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
3.3. Physiological regulation of UCP3 gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 233.3.1. Thyroid hormone and UCP3 gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
3.3.2. Adrenergic regulation of UCP3 gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3.3.3. Fatty acid and PPAR regulation of UCP3 gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . 244. UCP3 and a role in energy metabolism. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
4.1. UCP3 and energy metabolism as evidenced by linkage and association studies . . . . . . . . . . . . . . . . . 25
4.2. Investigations of skeletal muscle UCP3 mRNA and protein content in relation to energy
metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
4.3. Energy metabolism in mice over- and underexpressing UCP3. . . . . . . . . . . . . . . . . . . . . . . 265. UCP3 and the production of reactive oxygen species . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
5.1. Activation of UCP3 by reactive oxygen species . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
5.2. Inhibition of reactive oxygen species production by UCP3 . . . . . . . . . . . . . . . . . . . . . . . . 276. UCP3 and fatty acid metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
6.1. Physiological conditions showing a positive relationship between UCP3 and fatty acid metabolism . . . 28
6.2. Physiological conditions showing a negative relationship between UCP3 and fatty acid metabolism . . . 29
6.3. UCP3 as a mitochondrial exporter of fatty acids when fatty acid oxidation predominates . . . . . . . . . . 29
6.4. UCP3 as a mitochondrial exporter of non-metabolizable fatty acids . . . . . . . . . . . . . . . . . . . . . . . . . 30
6.5. UCP3 as a mitochondrial exporter of lipid peroxides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327. Physiological relevance of UCP3: a role in lipotoxicity? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
7.1. A unifying function for UCP3: protection against lipid-induced oxidative damage . . . . . . . . . . . . . . . 33
7.2. UCP3, lipotoxicity and type 2 diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 348. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 351. Introduction
Mitochondrial energy production is essential for life, as most cellular processes require energy that is
released from the hydrolysis of adenosine triphosphate (ATP). To maintain ATP levels, mitochondria are
equipped with a so-called electron transport chain, a series of protein complexes located in the inner mito-
chondrial membrane, in which potential energy derived from the breakdown of nutrients is converted into
ATP. In processes like glycolysis, b-oxidation and the TCA cycle, the carbon-rich nutrients fatty acids, car-
bohydrates and proteins are stepwise degraded to carbon dioxide and water together with the formation of
the reduced coenzymes NADH and FADH2. Inside mitochondria the reduced coenzymes are oxidized and
the liberated electrons are transferred through the protein complexes (I–IV) of the electron transport chain
towards molecular oxygen, which is subsequently reduced to water. According to the chemiosmotic theory
defined by Mitchell [1], the electron transfer leads to a proton transfer across the inner mitochondrial mem-
brane, resulting in an electrochemical gradient. If this proton gradient is high enough, protons flow back to the
mitochondrial matrix via the F0–F1-ATPase complex, thereby releasing the energy needed to phosphorylate
adenosine diphosphate (ADP) and generate ATP (oxidative phosphorylation) (Fig. 1). Theoretically, protons
can only flow back via the ATPase complex, resulting in a tight and efficient coupling between substrate deg-
radation and ATP formation. Indeed, chemical uncouplers like 2,4-dinitrophenol impair mitochondrial ATP
production and are detrimental to life.
In tightly coupled mitochondria, inhibition of the ATPase complex, either chemically or by depleting its
substrate ADP, would result in a profound increase in the proton gradient across the inner mitochondrial
membrane. The increased proton gradient prevents reduction of additional NADH or FADH2. As a resultant,

















Fig. 1. The electron transport chain: In mitochondria, NADH and FADH2, reducing equivalents derived from the degradation of food
substrates donate electrons to oxygen, the final electron acceptor, and the energy released during this process is used to pump protons from
the mitochondrial matrix to the intermembrane space. As a result, an electrochemical gradient is created across the inner mitochondrial
membrane. The exported protons flow back into the mitochondrial matrix through the F0–F1-ATPase and the energy generated is used to
synthesize ATP from ADP and inorganic phosphate (Pi).
P. Schrauwen et al. / Progress in Lipid Research 45 (2006) 17–41 19latter, however, is not observed in experimental settings: although profoundly blunted, isolated mitochondria
incubated in the presence of substrate but depleted of ADP still consume oxygen, suggesting, that under these
conditions the proton gradient can be lowered via routes other than the ATPase complex. The residual oxygen
consumption in the absence of ADP, referred to as state 4 respiration (see Fig. 2), indicates that mitochondrial
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in control mitochondria
Fig. 2. State 3 and state 4 respiration in isolated mitochondria: oxygen consumption in the presence of substrate (succinate), inorganic
phosphate and ADP is referred to as state 3 respiration. Under state 3 conditions, oxygen consumption is coupled to phosphorylation of
ADP to ATP. On depletion of ADP (and thus without ATP synthesis), mitochondria continue respiration at a much lower rate, referred to
as state 4 respiration. In this case, respiration is uncoupled from ATP synthesis and the proton gradient is lowered by proton leak.
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only exists as an apparent inevitable by-product of the mitochondrial system. Indeed, a small proportion of
mitochondrial oxygen consumption is due to uncontrolled leakage of electrons from the electron transport
chain from reduced oxygen to superoxide and hydrogen peroxide [2]. Remarkably, however, a major part
of mitochondrial uncoupling is not simply due to inefficiency of the system, but is highly regulated by the acti-
vation of destined mitochondrial uncoupling proteins. This conclusion is mainly drawn from research con-
ducted on the thermogenic capacity of brown adipose tissue (BAT). This tissue plays a major role in the
regulation of cold-induced and diet-induced thermogenesis via the production of heat [3]. Already in 1967
it was observed that respiration in mitochondria isolated from brown adipose tissue was coupled loosely to
ATP production [4], and it was demonstrated that this uncoupled respiration was activated by fatty acids
and inhibited by GTP, GDP, ATP and ADP [5,6]. Several years later, a 32 kDa protein was identified as
the binding site for these nucleotides, and from then onward, this protein would be referred to as the first dis-
covered uncoupling protein (UCP, later renamed as UCP1) [7]. Continuing research on this UCP1 for almost
30 years have shown that this UCP1 is essential for cold-induced thermogenesis and UCP1 ablated mice are
incapable of maintaining body temperature when exposed to cold [8].
Although the presence of UCP1 provides an explanation for the observed mitochondrial uncoupling in
mitochondria isolated from brown adipose tissue, UCP1 protein expression appears to be restricted to brown
adipose tissue mitochondria. Nevertheless, mitochondrial uncoupling is a phenomenon that can be observed
in mitochondria isolated from a variety of tissues. For example, it has been calculated that in vivo proton leak
in liver and skeletal muscle mitochondria may account for 20% of the basal oxygen consumption [9]. The
protein(s) responsible for the proton leak in these tissues had however not been identified. In 1997, however,
two UCP1 homologues were cloned with putative uncoupling activity: UCP2 [10] and UCP3 [11].
In contrast to UCP2, which is ubiquitously expressed [10], the expression of UCP3 is limited to skeletal
muscle, heart and brown adipose tissue [11], tissues with an important role in energy and substrate metabo-
lism. Extensive research on the regulation and the putative functions of these novel uncoupling proteins has
resulted in a vast amount of papers in the last 9 years. Notwithstanding the overwhelming number of studies
published, there appears to be no consensus yet on the primary function and the physiological implications of
UCP2 and UCP3. UCP2 among others has been implicated in the regulation of insulin secretion, neuropro-
tection and defense against ROS production. For more details on UCP2, however, the reader is referred to
several excellent reviews on the putative function of UCP2 [12–16]. In the present review, we will discuss
the literature available on the regulation and putative function of the skeletal muscle UCP3.
2. Uncoupling properties of UCP3
2.1. Mechanism of action for mitochondrial uncoupling
After many years of research, the mechanism by which the original mitochondrial uncoupling protein
UCP1 is able to induce uncoupling is still under debate. Mitochondrial uncoupling is achieved by a lowering
of the proton gradient, which can either be achieved by allowing protons to flow from the intermembrane
space into the matrix, or by the export of negatively charged anions from the matrix into the intermembrane
space. So far, the proposed mechanisms by which UCP1 uncouples can be summarized by two models. In the
first model, proposed by Klingenberg and Huang [17], UCP1 actually transports protons, and fatty acids facil-
itate this process by donating protons to proton-buffering amino acids in the channel within the UCP. In the
second model, sometimes referred to as the Skulachev/Garlid/Jezek hypothesis [18–20], UCP is involved in the
outward translocation of fatty acid anions from the matrix. In the latter model, neutral fatty acids flip-flop
over the inner mitochondrial membrane and donate a proton to the matrix. The resulting fatty acid anions,
which are not able to flip-flop back, are transported by UCP and pick up a proton in the intermembrane space.
In both models, fatty acids are essential for stimulating uncoupling activity, which is in accordance with the
general consensus that at least in experimental conditions, fatty acids stimulate, and nucleotides inhibit UCP1
induced mitochondrial uncoupling [5,21]. Therefore, regulation by fatty acids and/or nucleotides seems to be
an important criterion in determining whether the novel uncoupling protein UCP3 possesses uncoupling
activity.
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On its discovery it was, based on its homology with uncoupling protein-1, assumed that UCP3 also pos-
sesses mitochondrial uncoupling activity. In the search for evidence for uncoupling activity, most studies
reconstituted the UCP3 protein into liposomes or yeast cells and measured proton fluxes, oxygen consumption
and/or membrane potential. Jabůrek et al. [22] expressed human UCP3 in Escherichia coli and subsequently
reconstituted the protein into liposomes. Their results implicated that UCP3 is capable of catalyzing an elec-
trophoretic proton flux (qualitatively) similar to UCP1, and that this UCP3-mediated proton flux is dependent
on fatty acids [22]. Purine nucleotides, known to be potent inhibitors of UCP1, also inhibited proton transport
mediated by UCP3 in this proteoliposome model, although the effect was lower in comparison with UCP1
[22]. In another study, human uncoupling protein 3 was expressed in yeast cells, resulting in an increase in
the overall rate of oxygen consumption and a decrease in mitochondrial membrane potential [23]. Zhang
et al. [24] also used a UCP3-transfected yeast expression system and showed that state 4 respiration (i.e., res-
piration in absence of exogenous ADP), expressed as percentage of maximal respiratory capacity (FCCP-stim-
ulated respiration), was significantly increased. GDP, a potent inhibitor of UCP1, did not reverse the
uncoupling activity of UCP3.
Although these results implicate that UCP3 can possess uncoupling properties, subsequent studies showed
that the incorporation of UCP3 in yeast cells results largely in a deranged and non-physiological state, thereby
allowing an uncontrolled proton transport [25,26], which could explain the lack of GDP-inhibition on UCP3
induced uncoupling. In agreement, Harper et al. [27] revealed that the concentration of UCP3, at which yeast
mitochondria display obvious uncoupling, was 7-fold higher than physiological concentrations present in
rodent skeletal muscle, whereas with physiological concentrations only very little uncoupling was detected.
Transfection of UCP3 in L6 myocytes also resulted in uncoupling of respiration, which was unaffected by pur-
ine nucleotides and fatty acids, again suggesting that UCP3 overexpression results in uncontrolled uncoupling
due to improper folding of the protein or incomplete incorporation into the inner membrane, rather than rep-
resenting a physiological phenomenon [28]. The lack of inhibition of uncoupling activity by purine nucleotides
(and sometimes also the lack of activation by fatty acids), prerequisites for uncoupling action of UCP1, are
nowadays especially considered to be criteria for regulated uncoupling activity of UCP3.
2.3. Genetic manipulation of UCP3 in animals
The question of UCP3 being a true uncoupler has also been addressed in genetically modified mice over-
and underexpressing UCP3. Mice overexpressing human uncoupling protein-3, were shown to be hyperphagic
but lean, indicating that UCP3 is capable of increasing energy expenditure in vivo [29]. Oxygen consumption
measurements in skeletal muscle mitochondria of these mice revealed an increase in state 4 respiration, a
decrease in state 3 respiration and a 12% decrease in mitochondrial membrane potential, indicating mitochon-
drial uncoupling [29]. Similar to the reconstitution studies described above, the main criticism to these findings
was that overexpression of UCP3 might have resulted in non-physiological, uncontrolled uncoupling. Thus,
Cadenas et al. [30] studied whether the uncoupling observed in mice overexpressing UCP3 was native (i.e.,
uncoupling that can be inhibited by GDP and/or activated by fatty acids) or a non-native artefact (i.e., uncou-
pling that cannot be manipulated). They found that GDP had no effect on proton conductance in UCP3 over-
expressing mice. Also, they failed to detect a difference between UCP3 overexpressing mice and their wild-type
littermates with respect to uncoupling activated by fatty acids, leading to the conclusion that the uncoupling
effect measured in UCP3 transgenic mice is unregulated and an overexpressing artefact [30].
The criticism of non-physiological expression of UCP3 cannot be applied to studies that examined the effect
of UCP3 ablation on mitochondrial uncoupling. Unfortunately, such studies have not yet revealed a uniform
answer towards the question whether UCP3 activity is necessary for mitochondrial uncoupling. Thus, Vidal-
Puig et al. [31] reported a significant decrease in state 4 respiration, but unaffected state 3 in mice lacking
UCP3, indicating increased mitochondrial coupling [31]. In addition, Gong et al. [32] and Bezaire et al. [33]
showed that skeletal muscle mitochondria of UCP3 ablated mice displayed an increased protonmotive force,
but no difference in state 4 respiration. In a more physiological approach, Cline et al. [34] examined in vivo
mitochondrial uncoupling using 31P-nuclear magnetic resonance (NMR) in mice lacking UCP3. Mice lacking
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increased coupling between substrate oxidation and ATP production. In contrast, Cadenas et al. [30] reported
that the basal proton conductance in skeletal muscle mitochondria of UCP3-KO animals was similar to that of
their wild-type littermates.
Taken together, although overexpression of UCP3 does seem to result in mitochondrial uncoupling, this
uncoupling activity appears to be insensitive to GDP as is hence considered an experimental artefact. On
the other hand, data obtained in systems lacking UCP3 have not revealed uniform results. Therefore, there
is no conclusive evidence that UCP3 can act as a true uncoupling protein comparable to UCP1. However, this
does not exclude that UCP3 can function as a transporter of protons or fatty acid anions, thereby lowering the
proton gradient, albeit that such action might require different activators when compared to the classical,
thermogenic uncoupling protein UCP1.
3. Regulation of UCP3 gene expression
3.1. UCP3 gene structure and protein distribution
UCP3 was discovered through screening of a human skeletal muscle cDNA library for sequences homol-
ogous to UCP1. With this technique, Boss et al. [11] showed that two RNA transcripts for UCP3 exist, which
are predicted to encode a long (UCP3L; 312 amino acids) and a short (UCP3S; 275 amino acids) isoform of the
UCP3 protein. Solanes et al. [35] showed that the human UCP3 gene consists of 7 exons spread over 8.5 kb
and is located on chromosome 11 (11q13), adjacent to the UCP2 gene [35]. UCP3L and UCP3S are derived
from alternative splicing at the end of exon 6 and a polyadenylation signal present in intron 6 [35]. The long
and short isoforms only differ by a 37 amino acid residue on the C terminus and both variants showed a 57%
and 73% similarity in amino acid sequence in comparison with UCP1 and UCP2, respectively [11].
The translated sequence from the coding cDNA for UCP3L predicts 6 transmembrane domains and a
purine nucleotide binding domain, similarly to UCP1 and UCP2. The protein generated by the short
UCP3 transcript would theoretically lack the last transmembrane domain and the purine nucleotide binding
domain [11]. In human skeletal muscle, both UCP3 transcripts seem to be equally expressed [35], whereas in
rodents only the long UCP3 mRNA isoform is present [36]. Northern blot analysis on the expression pattern
of UCP3 in rats revealed that UCP3 mRNA is expressed abundantly in skeletal muscle and BAT but was
also present in cardiac muscle and white adipose tissue (WAT), although at much at lower levels [37]. At the
protein level, UCP3 was detected in skeletal muscle, BAT and cardiac muscle [38,39]. Comparison of cardiac
and skeletal muscle revealed that UCP3 protein content was highest in glycolytic muscle (white gastrocne-
mius), 2–3-fold lower in oxidative muscle (soleus) and 10-fold lower in cardiac muscle (Fig. 3) [39]. Also
in humans UCP3 protein content was highest in glycolytic, type 2 muscle fibers and lowest in oxidative, type
1 muscle fibers [40].
3.2. Potential transcriptional regulatory sites of the UCP3 gene
Analysis of the 5 0-flanking, promoter region of the human UCP3 gene revealed several potential sequences
that can act as binding sites for regulatory transcription factors. Among these, recognition motifs for muscle-
specific regulatory factors such as an E-box, a MEF2 binding site and a CCAC-box were identified [41,42].
Both MEF2 and the CCAC-box motif are important for transcriptional regulation of muscle-specific genes
[43], whereas the E-box is a binding site for the myogenic factor MyoD, a factor that is required for substantial
promoter activity of the UCP3 gene [44]. These regulatory factors help to understand the muscle-specific
expression pattern of UCP3.
Next to regulatory sites allowing muscle-specific expression of UCP3, the promoter region of UCP3 also
contains retinoic acid- and PPAR-responsive elements [41,42,44,45]. The presence of these PPAR-responsive
elements is in line with numerous physiological observations showing that high levels of plasma free fatty
acids, which are PPAR ligands, induce the expression of UCP3 [46–49]. In cell-transfection studies, Solanes
et al. [44] indeed showed that UCP3 gene transcription was initiated by PPARa and PPARd activation,
but not PPARc [44].
Fig. 3. UCP3 protein content in rat white gastrocnemius (WGM), soleus (SM) and cardiac (CM) muscle. Fat oxidative capacity is highest
in cardiac muscle and lowest in white gastrocnemius, indicating an inverse relationship between UCP3 and fat oxidative capacity. Data
taken from [39].
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[41,42,50]. Recent work by Solanes et al. [50] revealed that the thyroid-responsive element [TRE] coincided
with the reported site responsible for responsiveness to PPAR and retinoids, indicating that this site acts as
a multihormonal responsive element. In addition, the initiation of UCP3 gene transcription by retinoids
and thyroid hormone also requires MyoD [50]. Finally, the UCP3 promoter region contains a cAMP
response-like element [41], suggesting that UCP3 gene transcription may be activated by physiological stimuli
that involve cAMP as a second messenger, such as adrenergic stimulation.
3.3. Physiological regulation of UCP3 gene expression
Based on the binding sites in the promotor of UCP3, the anticipated physiological stimuli that regulate
UCP3 gene expression include thyroid hormone, adrenergic stimulation, PPAR activity and/or fatty acid lev-
els. Many rodent and human studies have been addressing the physiological regulation of UCP3, as will be
discussed below.
3.3.1. Thyroid hormone and UCP3 gene expression
Numerous publications reported that thyroid hormone status or thyroid hormone treatment is capable of
upregulating UCP3 mRNA and protein levels [51–57]. Lanni et al. [58] showed a 5-fold decrease in UCP3
mRNA levels in hypothyroid rats, while hyperthyroid rats displayed a 5-fold increase in UCP3 expression,
as compared to euthyroid rats. State 3 and state 4 respiration increased according to thyroid hormone status
(i.e., hypothyroid < euthyroid < hyperthyroid), and state 4 respiration correlated with UCP3 mRNA levels
[58]. De Lange et al. [55] observed a high similarity in the time course of increased skeletal muscle UCP3
expression, the decrease in mitochondrial respiratory efficiency and the increase in resting metabolic rate when
hypothyroid rats were given a single injection of triiodothyronine (T3). Maximal UCP3 expression (12-fold
over basal) was reached at 65 h after T3 injection and at this time-point, resting metabolic rate was increased
by 45%, state 4 respiration by 40% and membrane potential decreased by 8%, indicative of mitochondrial
uncoupling [55].
Using a NMR approach to estimate mitochondrial uncoupling (defined as the rate of TCA flux over ATP
synthesis), a decrease in mitochondrial coupling of approximately 60% was found upon 10 days of T3 treat-
ment, which correlated well with changes in UCP3 mRNA and protein levels [59]. The same technique was
applied in humans treated with T3 for three days and a 70% increase in muscle TCA flux, with unchanged
rate of ATP synthesis was found, indicating increased mitochondrial uncoupling [60]. Unfortunately, the level
of UCP3 was not determined in this study.
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gastrocnemius UCP3 mRNA levels and resting metabolic rate. However, mitochondrial state 4 respiration
rates were unaffected by the treatment nor did they correlate with resting metabolic rate [57]. In addition,
Gong et al. [32] reported that UCP3 null mice showed the same increase in resting oxygen consumption during
4 days of T3 treatment as wild-type mice, indicating that UCP3 is not necessary for the thyroid-induced
thermogenesis.
Taken together, although thyroid hormone can affect UCP3 mRNA expression and protein content, it is
not evident that such an increase in UCP3 affects mitochondrial uncoupling or thermogenesis. In that respect,
it is important to note that the effect of thyroid hormone on UCP3 gene expression might be indirectly med-
iated by changes in plasma free fatty acids, since thyroid hormone is well known to induce lipolysis [52].
3.3.2. Adrenergic regulation of UCP3 gene expression
Given that the UCP3 gene promoter contains cAMP responsive elements, induction of UCP3 gene expres-
sion by serial activation of b-adrenergic receptor-linked adenylate cyclase, cAMP-dependent protein kinase A,
and CRE binding protein, which binds directly to the UCP3 promoter region, is anticipated. Indeed, Nagase
et al. [61] observed induction of UCP3 mRNA expression by adding adrenaline or b2-adrenergic agonists to
L6 myotubes, an effect that could be abolished by b2-adrenergic antagonists. In rodents, most studies focused
on the effect of b3-adrenergic stimulation on UCP3 expression, but with conflicting results [62–64]. In that
respect, it is important to note that skeletal muscle is believed to lack the b3-adrenergic receptor subtype, sug-
gesting that potential effects of b3-adrenergic stimulation on UCP3 expression are indirect, probably via
changes in plasma free fatty acids levels due to stimulation of lipolysis. Indeed, Nakamura et al. [64] observed
a b3-stimulation of UCP3 gene expression, accompanied by increased plasma free fatty acid levels, whereas
Yoshitomi et al. [63] found a b3-induced downregulation of UCP3 together with decreased circulating free
fatty acids.
To unravel the effects of b-adrenergic stimulation on UCP3 mRNA expression from fatty acid effects, we
examined the effect of a 3-h infusion of dobutamine (a b1-agonist), salbutamol (a b2-agonist) as well as
salbutamol plus acipimox (a nicotinic-acid analogue blocking lipolysis) on UCP3 mRNA expression in
healthy, lean human subjects [65]. We found no change in skeletal muscle UCP3 mRNA expression upon
b1- or b2-adrenergic stimulation, but a significant decrease in UCP3 mRNA expression in the salbutamol plus
acipimox condition, in which plasma fatty acid levels were markedly reduced.
Together these results indicate that b-adrenergic stimulation has, if anything, only modest effects on UCP3
mRNA expression, most likely mediated by b-adrenergic induced changes in plasma fatty acid levels.
3.3.3. Fatty acid and PPAR regulation of UCP3 gene expression
Soon after the discovery of UCP3, one of the most contrasting findings – with respect to a putative role of
UCP3 in energy metabolism – was that caloric restriction for 5 days resulted in a 2–3-fold increase in UCP3
mRNA levels in lean and obese humans [48]. These data were confirmed in rodents, where it was shown UCP3
mRNA was induced 5.6-fold in rat tibialis anterior muscle after a 48-h fast, and that 24 h fasting induced a
3.5-fold increase in UCP3 mRNA in mice soleus muscle without affecting basal heat production in vitro [66].
Weigle et al. [49] were the first to establish that fasting-induced increases in plasma fatty acids were responsible
for the increase in UCP3 mRNA: the induction of UCP3 upon fasting could be mimicked by the acute eleva-
tion of fatty acids levels via infusion of Intralipid together with heparin, whereas other physiological fasting-
induced responses (a decrease in leptin and an increase in corticosterone levels) had no effect on UCP3
mRNA. The effects of acute elevation of plasma fatty acid levels on UCP3 mRNA induction have been con-
firmed in humans [47]. In addition, refeeding resulting in normalization of plasma fatty acid levels is paralleled
by a return of UCP3 mRNA to control values [67]. The importance of fatty acids in the regulation of UCP3 is
further underscored by the observation that in mice UCP3 mRNA is induced during postnatal development,
but only when mice were weaned on a diet rich in fatty acids [68]. To this evidence adds a long list of phys-
iological conditions such as high-fat feeding [49,68–75] and acute exercise [76–80] all characterized by
increased plasma fatty acid levels with concomitant increase in the mRNA expression of UCP3.
The induction of UCP3 by fatty acids is likely to be mediated by PPAR activity, as the UCP3 promotor
contains PPAR responsive elements. It is well recognized that fatty acids are natural ligands of PPARs and
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UCP3 mRNA by selective PPAR agonists has been demonstrated in cultured muscle cells [44,81,82]. In addi-
tion, ligands for RXR which heterodimerises with PPAR, also induce UCP3 mRNA expression [44,81,82].
Also in vivo studies showed that UCP3 mRNA can be induced by PPAR agonists in rodents although the
results are less straight forward [83–85]. So far, no human data have been published on the effect of PPAR
agonists on UCP3, however, we recently found that 8 weeks of rosiglitazone treatment increased UCP3 pro-
tein content by 25% in skeletal muscle of human diabetic patients (P. Schrauwen, M. Mensink, G. Schaart,
E. Moonen-Kornips, J-P. Sels, E.E. Blaak, A.P. Russell, M.K.C. Hesselink, unpublished observation).
4. UCP3 and a role in energy metabolism
Eight years after its discovery, the physiological function of UCP3 is still under debate. Although UCP3 has
been implicated in a large number of distinct physiological functions, consistent research lines over these years
have focused on potential roles for UCP3 in energy metabolism, fatty acid metabolism, and the production of
reactive oxygen species. In this and following sections, the possibility of UCP3 being involved in any of these
functions will be discussed and placed into the context of the earlier mentioned findings.
4.1. UCP3 and energy metabolism as evidenced by linkage and association studies
Based on its homology to UCP1 it was initially anticipated that UCP3 would fulfill a role similar to UCP1
in skeletal muscle, i.e., inducing thermogenesis. As humans lack brown adipose tissue (normally only present
shortly after birth), the mechanism by which we induce adaptive thermogenesis (an increase in energy expen-
diture in response to stimuli like cold, diet or adrenergic stimulation) is still unknown, but it is likely that skel-
etal muscle plays a pivotal role in adaptive thermogenesis. Therefore, shortly after the discovery of UCP3 in
skeletal muscle most research focused on a potential role for this protein in the regulation of energy metab-
olism in humans.
Following the discovery of a novel gene, genetic studies are often performed to indicate possible
relationships between the gene and its proposed function. To this end, geneticists use linkage and
association studies to examine whether genetic variation in the gene of interest is associated with a certain phe-
notype. In the case of UCP3, genetic studies conducted shortly after its discovery found that markers in the
vicinity of the UCP2 and UCP3 gene (which are only 7 kb apart) were very strongly linked (p < 0.0001) to
resting metabolic rate (RMR) [86]. In an early association study, polymorphisms in the UCP2 and UCP3 gene
were associated with sleeping metabolic rate and 24 h energy expenditure in Pima Indians, as measured in a
respiration chamber [87]. The same polymorphisms were also found to be associated with 24 h energy expen-
diture in a Danish population [88], as well as with exercise efficiency [89].
A polymorphism in exon 3 of the UCP3 gene was related to resting metabolic rate, both before and after
a period of overfeeding, but not with overfeeding-induced changes in resting metabolic rate [90], and a poly-
morphism in exon 5 was associated with resting metabolic rate in African American women, but not in cau-
casian [91]. However, in contrast to these positive associations, several studies reporting a lack of
association between polymorphisms in the UCP2/UCP3 gene and energy metabolism have been published
[92–94]. Many studies have also investigated the association between polymorphism in the UCP3 gene and
body weight regulation as a resultant of energy metabolism, but no consistent conclusion can be drawn
from these investigations, with both a substantial number of studies showing positive associations between
UCP3 and body weight and an equal number of studies showing no association at all (reviewed in [16]). It
should of course be realized that, especially in humans, body weight regulation is complex and not only
dependent on energy metabolism.
4.2. Investigations of skeletal muscle UCP3 mRNA and protein content in relation to energy metabolism
In 1998,we observed that the level ofmRNAexpression ofUCP3 in skeletalmuscle of Pima Indians correlated
positively with sleepingmetabolic rate (which accounts for60% of total energy expenditure in humans) [95]. In
addition, we and others observed that UCP3 mRNA and protein content was reduced after weight reduction,
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thermogenesis, has been associated with increases in UCP3 mRNA and protein content. Acute cold exposure in
mice resulted in a 3-fold increase inUCP3 protein content, accompanied by a pronounced lowering ofmitochon-
drial membrane potential and dissipation of energy as heat [98]. In humans exposed to mild cold for 60 h, we
showed that UCP3 protein content was not changed (yet), but did relate to sleeping metabolic rate and 24 h
energy expenditure [99]. In the same study, however, UCP3 mRNA expression was down regulated upon cold
exposure, disproving a relation between cold-induced thermogenesis and UCP3. The latter is further substanti-
ated by the notion that in mice lacking UCP1 cold-induced non-shivering thermogenesis is completely absent,
suggesting that UCP1 can completely account for cold-induced thermogenesis [100].
Several groups also investigated the relationship between UCP3 and energy metabolism in relation to endur-
ance exercise and training. Endurance trained athletes were found to be characterized by significantly lower lev-
els of UCP3 mRNA expression, which were negatively correlated with aerobic capacity (maximal oxygen
consumption: VO2,max) and mechanical energy efficiency [101] and with the slow component of VO2 kinetics
(also an indication of energy efficiency) [102]. Also longitudinal studies show that, in humans, UCP3 is rapidly
reduced by endurance training [103,104], although these studies did not examine a relationship with energy
metabolism. In contrast, most, but not all [105], training studies performed in rodents have observed an upreg-
ulation of UCP3 after endurance training [76,106–108]. Part of this controversy may be explained by the fact
that in rodent studies, UCP3 has been determined shortly after the last bout of exercise. In that context, both in
humans [74,78,80,109,110], and in rodents [76,77,79,111] acute exercise has been shown to upregulate UCP3
mRNA expression, an effect that has been attributed to increased plasma fatty acid levels [80].
Taken together these, and other studies, report associations between UCP3 and energy metabolism (see
also Section 3.3.1 thyroid hormone and UCP3 gene expression). However, only after the creation of transgenic
mice over- and underexpressing UCP3 it could directly be tested if UCP3 affects energy metabolism.
4.3. Energy metabolism in mice over- and underexpressing UCP3
In 2000 the first report on mice overexpressing UCP3 was published, showing that these mice were hyper-
phagic but lean, suggesting an UCP3-induced increase in resting metabolic rate [29]. However, as mentioned
above, these results were later questioned by the fact that the overexpression of UCP3 might have resulted in
non-physiological uncoupling due to improper insertion of the protein in the mitochondrial membranes. In
addition, results obtained in mice lacking UCP3 were not supportive of a role of UCP3 in energy metabolism.
Although mitochondria of these mice tended to be more tightly coupled [31,32], these mice had no apparent
phenotype, i.e., they were not obese and had normal metabolic rates. In addition, mice lacking UCP3 showed
normal responses to exercise, cold exposure and thyroid hormone [31,32]. In addition, mice lacking both
UCP1 and UCP3 could phenotypically not be distinguished from single UCP1 knock-out mice, illustrating
that UCP3 does not compensate for the uncoupling action of UCP1 [32].
In summary, although there is evidence for an association between UCP3 and energy metabolism, the gen-
eral consensus nowadays is that UCP3 is not a major regulator of skeletal muscle thermogenesis and/or body
weight. The presence of UCP3 in skeletal muscle is not a prerequisite for proper body weight regulation and,
as discussed previously, there is also no firm evidence that UCP3 functions as a true uncoupler. At best, UCP3
may contribute marginally to the energy requirements of skeletal muscle due to a small uncoupling effect for
yet undefined physiological reasons. It is important to note however that the data obtained since the discovery
of UCP3 have indicated that the process of mitochondrial uncoupling per se does have the potential to con-
tribute to body weight regulation, as for example the artificial uncoupling observed in mice overexpressing
UCP3 is accompanied by a lean phenotype [29].
5. UCP3 and the production of reactive oxygen species
5.1. Activation of UCP3 by reactive oxygen species
As mentioned previously, UCP3 does not mediate regulated mitochondrial uncoupling, i.e., cannot be
inhibited by nucleotides and/or activated by fatty acids. As the straightforward interpretation of this would
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pling protein requires presently unidentified activators. Indeed, Echtay et al. [112,113] initially indicated coen-
zyme Q as an obligatory factor for uncoupling activity of UCP1, UCP2 and UCP3. Thus, UCP1 expressed in
E. coli inclusion bodies did not show the expected fatty-acid dependent reduction of the proton gradient, how-
ever, addition of coenzyme Q10 rescued the fatty-acid inducible proton transport to values observed with
native UCP1 [112]. In a latter report, similar experiments with similar results were observed for UCP3
[113]. In a subsequent study, Echtay et al. [114] reported that this effect of coenzyme Q10 was actually due
to the production of superoxide. Thus, the activation of mitochondrial uncoupling by coenzyme Q10 was
abolished when superoxide dismutase was added to the medium, and the replacement of coenzyme Q10 by
xanthine plus xanthine oxidase, leading to the formation of superoxide, was similar to coenzyme Q10 able
to lower the mitochondrial proton gradient. This superoxide induced mitochondrial uncoupling was depen-
dent on the presence of fatty acids, and was inhibited by nucleotides, and is completely absent in mitochondria
isolated from skeletal muscle of UCP3 knock-out mice, indicating that the superoxide-induced mitochondrial
uncoupling in muscle is mediated by UCP3 [114].
In the electron transport chain, a small fraction of the electrons leak from the complexes I and III and
react with oxygen molecules, leaving superoxide radicals. Superoxide production is thus a natural occuring
process that can be considered as an inevitable side-effect of mitochondrial ATP production. An important
question is whether UCP3 is also activated by endogenously produced superoxides. To this end, Talbot
et al. [115] demonstrated that mitochondria respiring on the complex II substrate succinate produce large
amounts of reactive oxygen species and this production can be inhibited by the addition of rotenone, an inhib-
itor of complex I. This indicates, that the major fractions of electrons under this condition leak from complex
I. Next, Talbot et al. [115] showed that skeletal muscle mitochondrial uncoupling was indeed activated by this
endogenous superoxide production and could be inhibited by nucleotides. These data suggest that also in
physiological conditions, superoxide may be able to activate UCP3.
More details about the mechanisms of superoxide induced mitochondrial uncoupling also came from the
group of Brand, who showed that the superoxide-induced activation of UCP3 is mediated via lipid-peroxide
intermediates [116]. Thus, reactive oxygen species can interact with polyunsaturated fatty acids, forming reac-
tive aldehydes such as 4-hydroxy-2-nonenal (4HNE). The addition of 4HNE to mitochondria isolated from
skeletal muscle of wild-type mice caused mitochondrial uncoupling that could be inhibited by nucleotides,
but the 4HNE-induced lowering of the proton gradient was significantly reduced in UCP3 knock-out mice.
At present, the working model for activation of UCP3 by superoxide involves the peroxidation of polyunsat-
urated fatty acids in the mitochondrial membrane after which the subsequent formed reactive alkenals activate
UCP3 and lower the proton gradient across the inner mitochondrial membrane [117].
5.2. Inhibition of reactive oxygen species production by UCP3
As mentioned above, ROS are produced by the mitochondria as a side-effect of mitochondrial respiration.
In 1996, Skulachev hypothesized that the production of reactive oxygen species by mitochondria is dependent
on the proton gradient [118], for which evidence was found later [119]. Thus, lowering of the proton gradient,
by mitochondrial uncoupling, results in a reduction of mitochondrial ROS production. As there is a steep rela-
tionship between mitochondrial ROS production and proton gradient, mild uncoupling would already reduce
mitochondrial ROS production markedly [119]. Supportive for a potential role for UCP3 in regulating such
mild uncoupling was the observation that skeletal muscle mitochondria isolated from mice lacking UCP3 pro-
duced more superoxide anions in vitro and displayed increased in vivo ROS production when compared to
wild-type mice [31]. ROS production in liver, which does not express UCP3 in wild-type animals, was compa-
rable between UCP3 knock-out mice and wild-type mice, indicating that it was indeed the absence of UCP3 in
muscle that was responsible for the increased muscular ROS production [31]. Reactive oxygen species are
highly reactive and can lead to damage to DNA, RNA, lipids and proteins. In that respect, it has been
observed that mice lacking UCP3 have increased levels of oxidative damage to proteins, lipids and DNA [120].
In a recent report, overexpression of UCP3 at physiological levels (2.2–2.5-fold) in L6 muscle cells signif-
icantly decreased mitochondrial ROS production [121], although this effect was not due to a UCP3 effect on
mitochondrial proton gradient.
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linked UCP3 with the production of ROS is available. One study examined the effect of energy restriction,
known to increase lifespan in animals, on mitochondrial ROS production and UCP3 protein content. Rats
were energy restricted for 12 or 18 months, which decreased mitochondrial ROS production and oxidative
damage. The decrease in ROS production was accompanied by an increase in UCP3 protein content [122].
In addition, it has been shown that UCP3 protein content is reduced by 68% in 24-month-old rats compared
to young adult rats, and aging is known to be accompanied by (or even be due to) increased oxidative damage,
suggesting that the reduction of UCP3 may contribute to the latter [123].
Taken together, there is in vitro evidence that UCP3 can be activated by superoxides and lipid peroxides,
and that activation of UCP3 can reduce ROS production. Altogether, this points towards a negative feedback
loop between ROS production and subsequent lipid peroxidation on the one hand and mitochondrial uncou-
pling induced by UCP3 leading to reduction of ROS production on the other hand. However, as deduced from
physiological data and expression pattern of UCP3 such a role in ROS production seems to be linked to dis-
turbed fatty acid metabolism.
6. UCP3 and fatty acid metabolism
Next to a role in the regulation of ROS production, UCP3 has been consistently related to the metabolism
of fatty acids in skeletal muscle. This started with the early finding that UCP3 is rapidly upregulated in the
fasted state, which was the earliest observation that made researchers doubt about the role of UCP3 as a true
uncoupler. By now there is ample experimental data indicating that UCP3 is closely related to fatty acid
metabolism, which will be reviewed below.
6.1. Physiological conditions showing a positive relationship between UCP3 and fatty acid metabolism
The fasting induced increase in UCP3 mRNA and protein content is a consistent observation that has been
confirmed in many studies [48,49,124–128]. Tunstall et al. [127] showed that UCP3 mRNA expression was
increased 5-fold after 15 h, and 10-fold after 40 h of fasting in human skeletal muscle. Remarkably, however,
no effect of fasting on the expression of other (PPAR-regulated) genes involved in the uptake, transport, oxi-
dation, and re-esterification of fatty acids was observed in that time frame, suggesting a unique role for UCP3
in the regulation of FA homeostasis during fasting [127]. This is an important finding, as the upregulation of
UCP3 by fasting is sometimes simplified as a fatty acid-PPAR effect without physiological meaning. Indeed, as
described under Section 3.3.3 (fatty acid and PPAR regulation of UCP3 gene expression) UCP3 is upregulated
by high levels of fatty acids and PPAR-agonists. However, the finding by Tunstall et al. [127] suggests that the
fasting-induced induction of UCP3 reflects a physiological need for more UCP3 under these circumstances,
and is not simply a reflection of increased plasma fatty acid levels. This suggestion is underlined by the finding
that abolishing the increase in plasma fatty acids upon fasting via administration of the anti-lipolytic agent
nicotinic acid, only prevents upregulation of UCP3 in oxidative muscle, but not in glycolytic muscle [129].
In addition, fasting not only increases UCP3 at the mRNA level, but also at the protein level. It is important
to note that it is not self-evident that UCP3 protein levels follow mRNA expression. For example, acute exer-
cise rapidly upregulates UCP3 mRNA [74,78,80,109,110], whereas regular exercise (training) leads to a reduc-
tion of UCP3 protein content [103,104,130]. Thus upregulation of UCP3 by fasting cannot be reduced to a
simple fatty acid/PPAR-effect.
Next to fasting, high-fat feeding also has been shown to result in an upregulation of UCP3 mRNA and
protein content, both in rodents [49,68–72] and in humans [73–75]. In addition, the fasting-induced upreg-
ulation of UCP3 is rapidly restored upon refeeding a low-fat diet [131], but this restoration of UCP3 is
completely absent with high-fat refeeding [71]. Both the fasting- and high-fat induced upregulation of
UCP3 is most pronounced in glycolytic compared to oxidative muscle fibers [75,131]. These findings have
been interpreted as evidence that UCP3 may play a role in facilitating fat oxidation, as the glycolytic mus-
cle fibers would display a higher capacity to switch from glucose oxidation towards fat oxidation and the
fasting and high-fat diet induced upregulation of UCP3 in these muscle fibers could serve to facilitate fat
oxidation.
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The experiments described above suggest that UCP3 is upregulated under conditions in which plasma fatty
acids and fatty acid oxidation are high. Regarding the latter, the observation that UCP3 is highly expressed in
type 2b, non-oxidative glycolytic muscle fibers [40] is remarkable. Moreover, UCP3 protein content has been
shown to be very low in cardiac muscle, 2–3-fold higher in oxidative muscle (soleus) and 10-fold higher in
mixed, glycolytic skeletal muscle [39]. This negative relation between oxidative capacity and UCP3 expression
is not easily compatible with a major role of UCP3 in facilitating fatty acid oxidation.
In addition, endurance training, which is accompanied by an increased muscular fatty acid oxidation capac-
ity, leads to a reduction of UCP3 protein content in humans [103,104,130]. The reduction of UCP3 protein
content has been related to the increase in fatty acid oxidation, with the largest reduction in UCP3 in those
subjects [130] or muscle fibers [103] that have the highest fat oxidative capacity. Also weight reduction, known
to improve fat oxidative capacity in overweight subjects, is accompanied by a decrease in UCP3 [96,97,132].
With a less physiological, pharmacological approach it was shown that direct inhibition of fatty acid oxi-
dation via the administration of etomoxir, an inhibitor of mitochondrial fatty acid uptake via carnitine-pal-
mitoyl-transferase 1 (CPT1), rapidly upregulates UCP3 mRNA and protein content [133–136]. In addition,
patients suffering from riboflavin responsive multiple acylCoA dehydrogenase deficiency (RR-MAD), a rare
mitochondrial myopathy, who are characterized by severely hampered fat oxidation, display significant
increased levels of UCP3 mRNA and protein content. Treatment of these patients with riboflavin restored
fat oxidative capacity to control values accompanied by a return of UCP3 protein levels to control values
[137]. Taken together, these data indicate that UCP3 is not positively related to fat oxidative capacity, but
rather may be induced under conditions where fat oxidative capacity of the skeletal muscle is low.
Deduced from these data, three hypothesis have been formulated to explain the putative role of UCP3 in
fatty acid metabolism, which will be reviewed in the subsequent sections.
6.3. UCP3 as a mitochondrial exporter of fatty acids when fatty acid oxidation predominates
The mitochondrial oxidation of fatty acids involves the import of fatty acid into the mitochondrial matrix
through CPT1, requiring carnitine as a co-factor. At the cytosolic side, fatty acids are activated by conversion
to their CoA-esters. These fatty acyl-CoA esters will diffuse across the outer mitochondrial membrane and
reach the inter membrane space. As the inner mitochondrial membrane is impermeable to fatty acyl-CoA, con-
version to fatty acyl-carnitine by the action of the enzyme CPT1 facilitates fatty acid transport across the inner
mitochondrial membrane. In the mitochondrial matrix, fatty acyl-carnitine is subsequently reconverted to
fatty acyl-CoA and carnitine by the action of CPT2, after which it will be subject to b-oxidation and the result-
ing acetyl-CoA moieties will enter the TCA cycle. Please note that only fatty acids that are activated by the
conjugation to CoA can undergo b-oxidation. Importantly – at least for long-chain fatty acids – the enzyme
that converts fatty acids to fatty acyl-CoA is absent in the mitochondrial matrix and therefore long-chain fatty
acids are entirely dependent on the carnitine shuttle to allow their mitochondrial oxidation. Therefore, the car-
nitine shuttle exists not because fatty acids are unable to enter the mitochondrial matrix, but to channel the
fatty acids into the oxidation pathway [138].
Remarkably, inside the mitochondrial matrix acyl-CoA thioesterases have been found [139], whose enzy-
matic action would hydrolyze fatty acyl-CoA leaving a fatty acid anion and acyl-CoA. Given that the resultant
fatty acid cannot be diverted to b-oxidation, the presence of thioesterases, which liberate fatty acids from their
acyl-CoA is counterintuitive. It has been suggested that the physiological function of these thioesterases is the
regeneration of mitochondrial supply of CoA for use in other reactions of the TCA cycle and b-oxidation.
According to this suggestion, under conditions of increased mitochondrial entry of fatty acyl-CoA into the
mitochondria, the need for CoA in these reactions exceeds the available CoA in the matrix, and although
removal of CoA from fatty acyl-CoA will reduce the amount of fatty acids that can undergo oxidation, this
will have a less dramatic effect on overall fat oxidation than a shortage of CoA in the TCA cycle and b-oxi-
dation. Thus, thioesterase redistributes the available CoA in the matrix ensuring maintenance of fat oxidation.
A side-effect of thioesterase activity, however, is the release of fatty acids in the matrix, which will be
deprotonated due to the proton gradient leaving fatty acid anions inside the mitochondrial matrix. As the
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acids to fatty acyl-CoA [140], this fatty acid anion is trapped inside the mitochondrial matrix. Here,
Himms-Hagen and Harper [141] hypothesized that UCP3 would facilitate the outward transport of these fatty
acid anions from the mitochondrial matrix, consistent with the Skulachev/Garlid/Jezek hypothesis [18–20], to
the intermembrane space where the fatty acid anion can be protonated again and leave the intermembrane
space. In this way, UCP3 would protect mitochondria against deleterious effects of non-metabolizable fatty
acids, and in combination with mitochondrial thioesterase help to enhance fatty acid oxidation by delivering
CoA to the TCA cycle and b-oxidation [141].
In support of the hypothesis of Himms-Hagen, mice overexpressing UCP3 were found to be characterized
by increased levels of mitochondrial thioesterase [142]. Another study found that mice lacking the leptin recep-
tor displayed increased levels of both UCP3 and mitochondrial thioesterase in skeletal muscle and both genes
were concordantly downregulated by PPAR agonist treatment, suggesting that UCP3 and mitochondrial thi-
oesterase may be involved in the same pathway [143]. Similar results were observed by another research group,
showing that fasting and T3 treatment resulted in a concordant upregulation of UCP3 and mitochondrial thi-
oesterase [144]. Although these results can indeed be interpreted as supporting evidence for the Himms-Hagen
hypothesis, it cannot be ruled out that the gene expression of UCP3 and mitochondrial thioesterase are simply
regulated by similar transcription factors, as has been suggested recently [145].
Bezaire et al. [33] tested this hypothesis in a more direct fashion by examining fatty acid oxidation in mice
lacking UCP3, both in the fasting and the fed state. In both conditions, fatty acid oxidation tended to be
impaired in UCP3 knock-out mice, although the difference was only significant in the fed state. In a subse-
quent study [146], it was also shown that mice overexpressing UCP3 in the physiological range (2.3-fold)
had significantly higher 24h fat oxidation and increases in markers of fatty acid metabolism, such as CPT1,
fatty acid binding protein (FAPB) and b-hydroxyacylCoA dehydrogenase in skeletal muscle. In addition,
the amount of lipid in skeletal muscle was reduced too, suggesting that these mice display an increased fat oxi-
dative capacity as would be predicted by their hypothesis. In contrast, however, the same set of fatty acid oxi-
dative markers was found to be unchanged in UCP3 knock-out mice compared to wild-type mice. Finally, in a
recent study it was found that overexpression of UCP3 in the physiological range in L6 muscle cells specifically
increased palmitate oxidation production and did not affect glucose oxidation [121].
Together, these studies show that overexpression of UCP3 leads to a stimulation of fatty acid oxidation and
that a lack of UCP3 may impair fat oxidation. Although these data are consistent with the hypothesis that
UCP3 exports fatty acid anions derived from hydrolysis of fatty acylCoA esters by thioesterase action, several
findings, described in Section 6.2, are not compatible with the Himms-Hagen hypothesis, and the physiological
data to support the hypothesis is limited. In addition, although there is evidence that UCP3 can facilitate fatty
acid cycling in the inner mitochondrial membrane. Definite proof that UCP3 can function as an unidirectional
exporter of fatty acid anions, however, is still awaited.
6.4. UCP3 as a mitochondrial exporter of non-metabolizable fatty acids
At the same time that Himms-Hagen and Harper proposed their hypothesis of UCP3 being a fatty acid
anion exporter to facilitate fatty acid oxidation, we postulated the hypothesis that UCP3 may act as a fatty
acid anion exporter of fatty acids that entered the mitochondrial matrix via flip-flop and that could therefore
not be oxidized (Fig. 4) [130]. As mitochondrial membranes are lipid bilayers they are also permeable for neu-
tral fatty acids. By means of a so-called flip-flop mechanism, fatty acids can diffuse through these membranes,
and it has even been suggested that at the cellular level (plasma membrane) this is the major route for fatty
acid uptake [138,147]. However, because a proton gradient exists over the inner mitochondrial membrane,
fatty acids that flip-flop over this membrane will become deprotonated resulting in fatty acid anions.
Importantly, fatty acid anions are not able to flip-flop back across the membrane [148], nor can undergo
b-oxidation because the enzyme that converts long-chain fatty acids to fatty acyl-CoA is absent in the mito-
chondrial matrix [140]. Therefore, the inner mitochondrial membrane would accumulate fatty acid anions at
the side of the mitochondrial matrix. Moreover, these fatty acid anions could potentially leave the inner mito-
chondrial membrane and accumulate inside the mitochondrial matrix: this could occur either dissolved in the
matrix at very low concentrations or bound to the matrix-associated fatty acid binding proteins [149]. In the
Fig. 4. Schematic model of UCP3s putative function. The normal pathway for fatty acids to enter the mitochondrial matrix is via import
through CPT1, requiring carnitine as a co-factor (because the inner mitochondrial membrane is impermeable to fatty acyl-CoA). Please
note that only fatty acids that are activated by the conjugation to CoA can undergo b-oxidation and that – at least for long-chain fatty
acids – the enzyme that converts fatty acids to fatty acyl-CoA is absent in the mitochondrial matrix. However, as mitochondrial
membranes are lipid bilayers they are also permeable for neutral fatty acids. By means of a so-called flip-flop mechanism, fatty acids can
diffuse over these membranes, but because a proton gradient exists over the inner mitochondrial membrane, fatty acids that flip-flop over
this membrane will become deprotonated. Importantly, fatty acid anions are not able to flip-flop back across the membrane and therefore
the inner mitochondrial membrane would accumulate fatty acid anions at the side of the mitochondrial matrix. In the matrix (or at the
inner side of the membrane), these fatty acid anions would be prone to become peroxidized by the reactive oxygen species that are
produced in the electron transport chain and which are therefore present in the mitochondrial matrix. UCP3 protects these fatty acid
anions against peroxidation by facilitating outward transport. ACS, acyl-CoA synthase.
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become peroxidized by the reactive oxygen species that are produced as an obligatory side product of the elec-
tron transport chain and which are therefore present in the mitochondrial matrix. As peroxidized fatty acids
are highly reactive [150], they could damage DNA, RNA and proteins of the mitochondrial machinery, which
are mainly present in the mitochondrial matrix. Therefore, we postulated that UCP3 may serve as an exporter
of non-metabolizable fatty acid anions that entered the mitochondrial matrix via flip-flop, again consistent
with the Skulachev/Garlid/Jezek hypothesis [18–20]. At the side of the inner membrane space, the exported
fatty acid anions will be protonated again and may either flip-flop back into the matrix (leading to mitochon-
drial uncoupling via fatty acid cycling), or leave the inner mitochondrial membrane once the cellular fatty acid
concentration decreases. This hypothesis was based on observations in physiological studies that UCP3 is
upregulated under conditions in which the supply of fatty acids to the muscle exceeds the fat oxidative capac-
ity, such as fasting, high-fat feeding, acute exercise and in type 2b muscle fibers, whereas UCP3 is downreg-
ulated when the fat oxidative capacity is high (type 1 muscle fibers, endurance training). Under these
conditions where fatty acid supply is mismatched by fatty acid oxidation, fatty acids will accumulate in the
cytosol and the chance of fatty acids entering the mitochondrial matrix, and therefore the need for UCP3, will
be increased. Therefore, although our hypothesis shows similarities to the Himms-Hagen and Harper hypoth-
esis [141], the major differences are the source of the fatty acid anions and the fact that in our hypothesis UCP3
is not involved in mediating fatty acid oxidation, but merely protects the mitochondria against the deleterious
effects of neutral fatty acids.
After we postulated our hypothesis, we performed several experiments that could provide supportive
data. First, we used the potential of Etomoxir to inhibit CPT1, the rate-limiting step in the uptake of fatty
acyl-CoA in human subjects for 36 h, while consuming a high-fat diet to increase fatty acid supply. Accord-
ing to our hypothesis, this would be one of the most dramatic conditions in which UCP3 is needed, as both
the oxidative capacity is low and the supply of fat is high. As anticipated, we indeed found a 67% induction
of UCP3 protein content after 36 h of Etomoxir treatment, which was related to the Etomoxir-induced
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changes of UPC3 at the protein level convinced us that the result was not simply a transcriptional effect
of increased fatty acid levels, in fact plasma fatty acid levels were not increased after 36 h of etomoxir in
humans [134]. These findings were confirmed in rats, where we found that Etomoxir treatment for 8 days
resulted in a 2-fold decrease in CPT1 activity and a 2-fold increase in UCP3 [73]. Please note that due to
the partial block of CPT1 the fraction of fatty acids entering the mitochondria as their FA CoA esters is
limited and hence CoA availability in the matrix will not be limiting. This reduces the need for MTE1 to
hydrolyse FA-CoA esters. Thus, according to the Himms-Hagen hypothesis, a block on CPT1 would not
result in increased UCP3 content.
In a second study, we used the special characteristics of medium-chain fatty acids to test our hypoth-
esis. An important aspect of our [130] and Himms-Hagens hypothesis [141] is that neutral fatty acids
inside the matrix cannot be oxidized because they can not be converted to fatty-acyl CoAs inside the
matrix [151]. However, this is not true for medium-chain fatty acids: these fatty acids can be activated
inside the mitochondrial matrix and do not rely on CPT1 for mitochondrial uptake [140,152]. Thus, even
when neutral medium-chain fatty acids reach the mitochondrial matrix, they can be activated to fatty acyl-
CoA and directed to b-oxidation [153]. Obviously, these fatty acids do not need to (and should not) be
exported from the matrix, eliminating a role for UCP3 in the handling of these specific fatty acids. Thus,
there is no need for UCP3 to deal with increased levels of medium chain fatty acids upon consumption of
a high fat diet composed of medium chain fatty acids, this in contrast to the anticipated increase on a
high fat diet containing predominantly long chain fatty acids. To test this, we fed rats high-fat diets
for 14 days, the fat source comprised entirely of either long-chain fatty acids or medium-chain fatty acids,
and found that UCP3 protein content was increased 2-fold upon long-chain high-fat feeding, but not
affected at all after medium-chain high-fat feeding [39]. This differential response in UCP3 to the two diets
was accompanied by a similar rise in plasma free fatty acid levels and could not be explained by a PPAR
effect, as other PPAR-responsive genes were similarly affected by the diets [39]. Again these data support
our hypothesis that UCP3 is involved in the export of fatty acids that cannot be metabolized from the
mitochondrial matrix.
In addition to these studies, the observations that UCP3 protein content (a) is negatively related to fat oxi-
dative capacity [39,40], (b) is decreased by endurance training in relation to the increase in fatty acid oxidation
[130], (c) follows changes in fat oxidative capacity in patients suffering from riboflavin responsive multiple
acylCoA dehydrogenase deficiency (RR-MAD) before and after riboflavin treatment [137] and (d) is specifi-
cally increased in glycolytic muscle fibers upon fasting and high-fat feeding [75,131], all are consistent with the
hypothesized role of UCP3 being a fatty acid anion exporter of non-metabolizable fatty acids. In this hypoth-
esis, lack of UCP3 would lead to the accumulation of fatty acid anions in the mitochondrial matrix or at the
matrix side of the inner mitochondrial membrane, and these fatty acids would be prone to become peroxidized
by reactive oxygen species and could subsequently lead to damage to the mitochondrial machinery. In that
context, the finding that mice lacking UCP3 display impaired fatty acid oxidation [33] and have increased lev-
els of oxidative damage to proteins, lipids and DNA [120] is consistent too, although these effects can also be
explained by the Himms-Hagen and Harper hypothesis, as by a direct effect of UCP3 on lowering of reactive
oxygen species.
Taken together, there are multiple physiological observations that fit the concept of UCP3 being an exporter
of fatty acid anions under conditions when not all fatty acids can be oxidized. In contrast to the Himms-Hagen
hypothesis, UCP3 would not facilitate fatty acid oxidation, but both hypothesis predict that lack of UCP3
would lead to lipid-induced damage to the mitochondrial machinery. However, definite proof that UCP3
can function as a unidirectional exporter of fatty acid anions is not available to date, but is eagerly awaited.
6.5. UCP3 as a mitochondrial exporter of lipid peroxides
In 2003, Goglia and Skulachev [154] proposed a third, closely related hypothesis regarding the physiolog-
ical role of UCP3 in fatty acid metabolism. According to their hypothesis, UCP3 is involved in the transfer of
fatty acid peroxides from the inner to the outer leaflet of the inner mitochondrial membrane, thereby extend-
ing the fatty acid cycling hypothesis [154]. In contrast to the previous two hypotheses, this hypothesis was
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and Skulachev the antioxidant capacity of UCP3 is too prominent to be fully explained by a mild uncoupling
effect of UCP3. They assumed that fatty acids at the matrix side of the inner mitochondrial membrane are
attacked by reactive oxygen species, resulting in lipid peroxides in the inner leaflet of the inner mitochondrial
membrane. These lipid peroxides are expected to be unable to flip-flop to the outer leaflet of the membrane
and, as these lipid peroxides are highly reactive, they could lead to major damage to components of the mito-
chondrial matrix. Goglia and Skulachev, therefore, proposed that UCP3 is involved in the outward translo-
cation of these lipid peroxides. Indeed, UCPs were recently shown to be able to facilitate lipid peroxide cycling
[155]. According to the authors, this function of UCP3 would be important as, in contrast to the inter mem-
brane space, oxidative damage to components in the mitochondrial matrix, for example, mtDNA would have
deleterious effects on overall mitochondrial function. In that respect, damage to mtDNA has been reversely
correlated with longevity in mammals [156]. The importance of reducing oxidative damage in the matrix is
also illustrated by the fact that knock-out of the cytosolic superoxide dismutase results in only a mild pheno-
type, whereas the knock-out of matrix superoxide dismutase results in a neonatal lethal phenotype character-
ized by mtDNA oxidative damage as well as respiratory chain and Krebs cycle abnormalities [157–159]. In this
way, UCP3 has a protective function against oxidative damage that would exceed the effect of UCP3 on mild
uncoupling only.
It should be noted that the hypothesis of Goglia and Skulachev [154] only differs slightly from the hypoth-
esis that we initially postulated [130] and recently updated [160]. Whereas our hypothesis was purely based on
UCP3 data obtained in physiological studies in which lipid metabolism was manipulated, and on the assump-
tion that UCP3 can export fatty acid anions, Goglia and Skulachev started off from the observation that
UCP3 has antioxidant capacity. Importantly, however, the data from most, if not all, physiological studies
also perfectly fit with the Goglia and Skulachev hypothesis. The physiological observations, however, do
not provide conclusive evidence if UCP3 indeed exports fatty acid anions to prevent mitochondria from per-
oxidation or actually export the peroxidized fatty acid anions. More importantly, however, both hypotheses
predict that UCP3 protects the mitochondrial matrix from the deleterious effects of fatty acids.
7. Physiological relevance of UCP3: a role in lipotoxicity?
7.1. A unifying function for UCP3: protection against lipid-induced oxidative damage
As reviewed above, there appears consensus that the physiological function of UCP3 is either involved in
fatty acid metabolism or in the regulation of the production of reactive oxygen species. Whereas the evidence
for a role of UCP3 in the production of reactive oxygen species mainly comes from reconstitution studies and
in vitro assays in isolated mitochondria from transgenic animals, the suggestion that UCP3 is involved in fatty
acid handling is based on observations in physiological studies, but direct evidence is lacking. It is, however,
quite possible that the truth is somewhere in between: UCP3 may be involved in the regulation of ROS
production, but specifically under conditions of mitochondrial fat accumulation. In that respect, the finding
that 4-hydroxynonenal activates UCP3 [116] provided a plausible link between the two proposed physiological
functions: When fatty acid supply to the mitochondria exceeds the oxidative capacity, fatty acids will
accumulate in the sarcoplasm. Under these circumstances, the load of fatty acids on the mitochondrial
membrane will increase and fatty acids may reach the inner leaflet of the inner mitochondrial membrane.
Reactive oxygen species formed in the mitochondrial matrix may attack the fatty acids in the mitochondrial
membrane, leading to the formation of lipid peroxides. These peroxides subsequently activate UCP3 leading
to a lowering of the proton gradient across the inner mitochondrial membrane, which will subsequently reduce
mitochondrial ROS production. Whether in this model UCP3 (a) exports fatty acid anions to prevent them
from peroxidation, (b) transports the actual peroxides – both leading to mitochondrial uncoupling via the
fatty acid cycling hypothesis and preventing peroxide-induced damage to the mitochondrial machinery- or
(c) only directly reduces ROS production by inducting proton transport after activation by lipid-peroxides,
should be the topic of further study. However, regardless of the exact mechanism of action of UCP3, the phys-
iological implication of all three hypotheses [116,130,154] is that UCP3 protects the mitochondria against




inner mitochondrial membrane ↑
UCP3↓
FA supply exceeds oxidative capacity
ROS ↑ 
FA anion export ↓
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Peroxides accumulation ↑
Fig. 5. A unifying mechanism how UCP3 may be involved in the protection against lipid-induce oxidative damage. When fatty acid
supply to muscle mitochondria exceeds the oxidative capacity, fatty acids may accumulate in the mitochondrial inner membrane. In the
mitochondrial matrix, reactive oxygen species are formed that may attack fatty acids leading to lipid peroxides. As these peroxides are
highly reactive, their accumulation could lead to oxidative damage to DNA, RNA and proteins present in the matrix, the side where the
mitochondrial machinery is located. UCP3 could protect against this mitochondrial damage by (a) exporting the fatty acid anions from the
matrix side of the inner mitochondrial membrane (b) directly lowering ROS production by mild uncoupling or (c) by exporting lipid
peroxides from the matrix side of the inner mitochondrial membrane. The effect of reduction of UCP3 is depicted by arrows. The dotted
line indicates a negative feedback loop between lipid peroxides and UCP3, in which lipid peroxides are able to activate UCP3. ROS,
reactive oxygen species.
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A putative role for UCP3 in the protection of mitochondria against lipid-induced oxidative damage is well
compatible with the upregulation of UCP3 in conditions of mitochondrial fat accumulation. On the other hand,
the fact that UCP3 is downregulated when the need for UCP3 is low (because of a high fat oxidative capacity),
such as after endurance training [130] or in highly oxidative muscles [39,40], suggests that cells prefer low UCP3
levels. This might be because high levels of UCP3 and the concomitant mild uncoupling may reduce mitochon-
drial energy efficiency, which could help to understand the early observations of a relationship between UCP3
and energy efficiency (see Section 4). However, low levels of UCP3 that are not compensated for by a high fat
oxidative capacity are expected to deteriorate mitochondrial function, for which some evidence is provided by
mice lacking UCP3 that display increased levels of oxidative damage to proteins, lipids and DNA [120].
One obvious condition, in which UCP3 may be involved in lipid-induced mitochondrial damage, is type 2
diabetes mellitus. Type 2 diabetic patients are characterized by a reduced fat oxidative capacity [161,162],
increased plasma free fatty acid levels [163,164] and increased accumulation of muscular fat [165,166]. With
these characteristics, increased UCP3 levels would be expected in these patients. However, we have previously
found that, at the protein level, UCP3 is reduced by 50% in type 2 diabetic patients [167]. Recently, we have
confirmed this observation by comparing skeletal muscle UCP3 protein content in type 2 diabetic patients,
pre-diabetic subjects and healthy controls. We found that UCP3 protein content was reduced by 40%, in
diabetic patients but most important, a similar reduction was already observed in the pre-diabetic state (sub-
jects with impaired glucose tolerane), and these reductions were not due to decreased mitochondrial density. In
addition, we found that the decreased levels of UCP3 in type 2 diabetic subjects could be restored by TZD
treatment, which improves the diabetic state in these patients [176]. These data suggest that the reduced levels
of UCP3 in (pre-) diabetic patients might reflect an unwanted, pathophysiological condition and would predict
that these patients have a reduced protection against lipid-induced oxidative mitochondrial damage. In that
context, it is very interesting to note that a diminished mitochondrial oxidative capacity and function has
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resistant subjects and/or type 2 diabetic patients are characterized by elevated levels of 4-hydroxynonenal
[170], increased damage to mitochondrial structures [171], have an increased prevalence of mitochondrial
DNA damage [172], and display a reduced mitochondrial function [173]. These observations suggest that
the reduced levels of UCP3 in the pre-diabetic state may be involved in a reduced protection against lipid-
induced oxidative damage to mitochondria, resulting in the deterioration of mitochondrial function as
observed in the diabetic state. In that respect, the parallel with aging is interesting, as elderly persons are also
characterized by mitochondrial dysfunction [174], accumulation of ROS-induced mutations in control sites of
mitochondrial DNA replication [175], and a reduction of UCP3 levels [123].
One argument that could be raised against an important role for UCP3 in the development of type 2 dia-
betes mellitus is the finding that UCP3 knock-out mice, despite displaying increased levels of oxidative mito-
chondrial damage [120] do not develop type 2 diabetes. Against this argument, we recently observed that mice
lacking UCP3 were indeed characterized by increased levels of lipid peroxidation when fed a low-fat diet, but
that on a high-fat diet these mice displayed a remarkable capability of limiting lipid peroxidation by reducing
the accumulation of fatty acids in skeletal muscle. Although the mechanism behind this adaptation still
deserves in depth investigation, the observation shows that results obtained in UCP3 knock-out mice should
be interpreted carefully, and the adaptive capacity to reduce muscular fat levels in UCP3/ mice may well
explain why these mice have no apparent phenotype such as obesity and diabetes.
8. Conclusion
The discovery of the mitochondrial uncoupling protein-3 was received with great enthusiasm by researchers
working in the field of body weight regulation. As with many novel obesity genes discovered in the last decade,
the hope was that UCP3 could be a target for future prevention and treatment of overweight and obesity in
order to fight the growing prevalence of these disorders. Like the majority of these novel obesity genes, how-
ever, hope vanished rapidly when it became evident that UCP3 does not display major uncoupling activity,
i.e., is not a major regulator of human energy expenditure. Consistent data gathered over the years shows that
UCP3 is closely related to fatty acid metabolism and UCP3 gene expression is rapidly induced by elevated
circulating fatty acid levels. The current evidence points towards a function for UCP3 in the regulation of
mitochondrial ROS production (deduced from mainly in vitro experiments), or the export of fatty acid
anions/peroxides from the matrix-side of the mitochondrial inner membrane (mainly deduced from physiolog-
ical experiments). So far, definitive (and generally accepted) proof is lacking for all functions of UCP3 and
there is urgent need for experiments that combine in vitro experiments with physiological, preferably
in vivo studies to establish UCP3s function. Regardless of its exact physiological function, however, the
in vivo role of UCP3 seems to be related to the protection of mitochondria against lipid-induced oxidative
damage. In that respect, muscular lipotoxicity, linked to the development of type 2 diabetes and among others
a direct consequence of increased body fat mass, may be prevented by the induction of UCP3, making this
protein a target for the prevention of obesity-induced type 2 diabetes mellitus.
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